Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study

被引:129
作者
Bhanpuri, Nasir H. [1 ]
Hallberg, Sarah J. [2 ]
Williams, Paul T.
McKenzie, Amy L. [1 ]
Ballard, Kevin D. [3 ]
Campbell, Wayne W. [4 ]
McCarter, James P. [1 ,5 ]
Phinney, Stephen D. [1 ]
Volek, Jeff S. [1 ,6 ]
机构
[1] Virta Hlth, San Francisco, CA 94105 USA
[2] Indiana Univ Hlth Arnett, Medically Supervised Weight Loss, Lafayette, IN USA
[3] Miami Univ, Dept Kinesiol & Hlth, Oxford, OH 45056 USA
[4] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA
[5] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA
[6] Ohio State Univ, Dept Human Sci, Columbus, OH 43210 USA
关键词
Ketosis; Carbohydrate restriction; Type diabetes; Cardiovascular disease; Risk factor; Atherogenic dyslipidemia; Inflammation; Blood pressure; Antihypertensive medication; Continuous remote care; DENSITY-LIPOPROTEIN CHOLESTEROL; C-REACTIVE PROTEIN; ISCHEMIC-HEART-DISEASE; BLOOD-CELL COUNT; LOW-FAT DIETS; INSULIN-RESISTANCE; APOLIPOPROTEIN-B; PARTICLE NUMBER; VASCULAR EVENTS; KETOGENIC DIET;
D O I
10.1186/s12933-018-0698-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiovascular disease (CVD) is a leading cause of death among adults with type 2 diabetes mellitus (T2D). We recently reported that glycemic control in patients with T2D can be significantly improved through a continuous care intervention (CCI) including nutritional ketosis. The purpose of this study was to examine CVD risk factors in this cohort. Methods: We investigated CVD risk factors in patients with T2D who participated in a 1 year open label, non-randomized, controlled study. The CCI group (n = 262) received treatment from a health coach and medical provider. A usual care (UC) group (n = 87) was independently recruited to track customary T2D progression. Circulating biomarkers of cholesterol metabolism and inflammation, blood pressure (BP), carotid intima media thickness (cIMT), multi-factorial risk scores and medication use were examined. A significance level of P < 0.0019 ensured two-tailed significance at the 5% level when Bonferroni adjusted for multiple comparisons. Results: The CCI group consisted of 262 participants (baseline mean (SD): age 54 (8) year, BMI 40.4 (8.8) kg m(-2)). Intention-to-treat analysis (% change) revealed the following at 1-year: total LDL-particles (LDL-P) (-4.9%, P = 0.02), small LDL-P (-20.8%, P = 1.2 x 10(-12)), LDL-P size (+ 1.1%, P = 6.0 x 10(-10)), ApoB (-1.6%, P = 0.37), ApoA1 (+ 9.8%, P < 10(-16)), ApoB/ApoA1 ratio (-9.5%, P = 1.9 x 10(-7)), triglyceride/HDL-C ratio (-29.1%, P < 10(-16)), large VLDL-P (-38.9%, P = 4.2 x 10(-15)), and LDL-C (+ 9.9%, P = 4.9 x 10(-5)). Additional effects were reductions in blood pressure, high sensitivity C-reactive protein, and white blood cell count (all P < 1 x 10(-7)) while cIMT was unchanged. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk score decreased -11.9% (P = 4.9 x 10(-5)). Antihypertensive medication use was discontinued in 11.4% of CCI participants (P = 5.3 x 10(-5)). The UC group of 87 participants [baseline mean (SD): age 52 (10) year, BMI 36.7 (7.2) kg m(-2)] showed no significant changes. After adjusting for baseline differences when comparing CCI and UC groups, significant improvements for the CCI group included small LDL-P, ApoA1, triglyceride/HDL-C ratio, HDL-C, hsCRP, and LP-IR score in addition to other biomarkers that were previously reported. The CCI group showed a greater rise in LDL-C. Conclusions: A continuous care treatment including nutritional ketosis in patients with T2D improved most biomarkers of CVD risk after 1 year. The increase in LDL-cholesterol appeared limited to the large LDL subfraction. LDL particle size increased, total LDL-P and ApoB were unchanged, and inflammation and blood pressure decreased.
引用
收藏
页数:16
相关论文
共 74 条
[1]   Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome [J].
Adiels, Martin ;
Olofsson, Sven-Olof ;
Taskinen, Marja-Riitta ;
Boren, Jan .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (07) :1225-1236
[2]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[3]  
[Anonymous], 2017, Diabetes Care, V40, pS33, DOI [10.2337/dc17-S007, DOI 10.2337/DC17-S007]
[4]  
[Anonymous], 2017, National Diabetes Statistics Report, 2017. National Diabetes Statistics Report, P1
[5]   Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis [J].
Arca, Marcello ;
Pigna, Giovanni ;
Favoccia, Carla .
CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (06) :684-686
[6]  
Asher Jordan, 2007, J Clin Hypertens (Greenwich), V9, P622, DOI 10.1111/j.1524-6175.2007.06639.x
[7]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[8]   Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel [J].
Barter, PJ ;
Ballantyne, CM ;
Carmena, R ;
Cabezas, MC ;
Chapman, MJ ;
Couture, P ;
De Graaf, J ;
Durrington, PN ;
Faergeman, O ;
Frohlich, J ;
Furberg, CD ;
Gagne, C ;
Haffner, SM ;
Humphries, SE ;
Jungner, I ;
Krauss, RM ;
Kwiterovich, P ;
Marcovina, S ;
Packard, CJ ;
Pearson, TA ;
Reddy, KS ;
Rosenson, R ;
Sarrafzadegan, N ;
Sniderman, AD ;
Stalenhoef, AF ;
Stein, E ;
Talmud, PJ ;
Tonkin, AM ;
Walldius, G ;
Williams, KMS .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) :247-258
[9]  
Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI [10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000530]
[10]  
Bertsch Ruth Ann, 2015, Perm J, V19, P4, DOI 10.7812/TPP/14-237